Wellington Shields Capital Management LLC Purchases Shares of 2,140 iShares Biotechnology ETF (NASDAQ:IBB)

Wellington Shields Capital Management LLC acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,140 shares of the financial services provider’s stock, valued at approximately $294,000.

Other large investors also recently modified their holdings of the company. Future Financial Wealth Managment LLC bought a new stake in iShares Biotechnology ETF in the 1st quarter valued at $27,000. Pacifica Partners Inc. grew its stake in shares of iShares Biotechnology ETF by 118.2% in the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock valued at $33,000 after acquiring an additional 130 shares in the last quarter. Crewe Advisors LLC increased its position in iShares Biotechnology ETF by 42.9% during the fourth quarter. Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock worth $35,000 after acquiring an additional 78 shares during the period. YHB Investment Advisors Inc. bought a new position in iShares Biotechnology ETF during the first quarter worth about $37,000. Finally, Northwest Financial Advisors acquired a new stake in iShares Biotechnology ETF in the 4th quarter worth about $42,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ:IBB traded up $1.29 on Wednesday, reaching $140.15. 536,817 shares of the company’s stock were exchanged, compared to its average volume of 1,611,532. iShares Biotechnology ETF has a twelve month low of $111.83 and a twelve month high of $141.16. The company has a fifty day moving average of $135.75 and a 200-day moving average of $135.15.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.